2616 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CStone Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.96 |
| 52 Week High | HK$2.95 |
| 52 Week Low | HK$0.80 |
| Beta | 0.21 |
| 11 Month Change | 5.38% |
| 3 Month Change | 53.13% |
| 1 Year Change | -20.97% |
| 33 Year Change | -81.47% |
| 5 Year Change | -82.56% |
| Change since IPO | -84.76% |
Recent News & Updates
Recent updates
There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise
Oct 04
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified
May 12Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Shareholder Returns
| 2616 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 5.4% | -0.3% | -0.6% |
| 1Y | -21.0% | -15.2% | 9.6% |
Return vs Industry: 2616 underperformed the Hong Kong Biotechs industry which returned -15.2% over the past year.
Return vs Market: 2616 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 2616 volatility | |
|---|---|
| 2616 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2616 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2616's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 164 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
CStone Pharmaceuticals Fundamentals Summary
| 2616 fundamental statistics | |
|---|---|
| Market cap | HK$2.50b |
| Earnings (TTM) | -HK$152.89m |
| Revenue (TTM) | HK$490.48m |
5.1x
P/S Ratio-16.4x
P/E RatioIs 2616 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2616 income statement (TTM) | |
|---|---|
| Revenue | CN¥456.53m |
| Cost of Revenue | CN¥133.65m |
| Gross Profit | CN¥322.89m |
| Other Expenses | CN¥465.20m |
| Earnings | -CN¥142.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 70.73% |
| Net Profit Margin | -31.17% |
| Debt/Equity Ratio | 65.5% |
How did 2616 perform over the long term?
See historical performance and comparison